A Phase 2 interventional study of Celecoxib and Placebo in Schizophrenia, sponsored by Pfizer. Completed at 17 sites in 6 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2009-03-16.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Schizophrenia by Pfizer — none open to participants now, none under way, none of them phase 3. Schizophrenia · Pfizer.
Among the 35 studies in Schizophrenia by Pfizer, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2003, is one of 10 in phase 2, and was the 20th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 35 studies in Schizophrenia by Pfizer is open now. The open studies under Schizophrenia, anywhere →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 40 across the 34 interventional studies. Of the 31 that completed or were terminated, 6 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Schizophrenia by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy and safety of celecoxib as add-on therapy to risperidone versus risperidone alone in patients with schizophrenia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Celecoxib
Drug: Placebo
200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score
Time frame: Week 11
Patient-Reported Outcomes using Treatment Satisfaction Questionnaire for Medication
Time frame: Week 4 and 11
Physical examination
Time frame: Week 11
Laboratory exams
Time frame: Weeks 1, 2, 4, 6, 8, 11
Change from baseline in Global Improvement and Efficacy Index scores of Clinical Global Impressions scale of Psychosis
Time frame: Weeks 4, 6, and 11
Change from baseline in total PANSS score
Time frame: Weeks 4 and 6
Change from baseline in PANSS-derived Brief Psychiatric Rating Scale score
Time frame: Weeks 4, 6, and 11
Change from baseline in combined PANSS Negative plus General Psychopathology Subscale Score and the separate PANSS Psychopathology Subscale Scores
Time frame: Weeks 4, 6, and 11
Change from baseline in PANSS five-factor component scores
Time frame: Weeks 4, 6, and 11
Time to onset of clinically meaningful improvement in total PANSS score
Time frame: Weeks 1, 2, 4, 6, 8, and 11
Adverse events
Time frame: Weeks 1, 2, 4, 6, 8, 11
The record gives a start of Mar 2003 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib